ArticleEBioMedicine2018
A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.
Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Structure, function, and implications of fucosyltransferases in health and disease.Nature communications · 2025Review
- Overexpression and clinicopathological significance of zinc finger protein 71 in hepatocellular carcinoma.World journal of hepatology · 2025Article
- Multiomics of Aging and Aging-Related Diseases.International journal of molecular sciences · 2024Review
- Plasma ofCS-modified CD44 predicts the survival of patients with lung cancer.Cancer science · 2024Observational
- Scientific figures interpreted by ChatGPT: strengths in plot recognition and limits in color perception.NPJ precision oncology · 2024Article
- Bioinformatics Illustrations Decoded by ChatGPT: The Good, The Bad, and The Ugly.bioRxiv : the preprint server for biology · 2023Article
- Preoperative computed tomography-based tumoral radiomic features prediction for overall survival in resectable non-small cell lung cancer.Frontiers in oncology · 2023Article
- Review
- Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival.International journal of molecular sciences · 2022Article
- Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks.Biomolecules · 2022Article
- High-risk early-stage lung adenocarcinoma patients are identified by an immune-related circadian clock gene signature.Journal of thoracic disease · 2022Article
- Article
- A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer.International journal of molecular sciences · 2021Article
- Immune-Omics Networks ofCancers · 2021Article
- Molecular Analysis ofInternational journal of molecular sciences · 2021Article
- A Novel Nomogram Based on Immune Scores for Predicting Survival in Patients with Early-Stage Non-Small Cell Lung Cancer (NSCLC).Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- The expression, significance and function of cancer susceptibility candidate 9 in lung squamous cell carcinoma: A bioinformatics and in vitro investigation.International journal of oncology · 2019Article
- A molecular and staging model predicts survival in patients with resected non-small cell lung cancer.BMC cancer · 2018Article
- Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer.EBioMedicine · 2018Article
- A Quest for New Cancer Diagnosis, Prognosis and Prediction Biomarkers and Their Use in Biosensors Development.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to develop a multi-gene assay predictive of the clinical benefits of chemotherapy in non-small cell lung cancer (NSCLC) patients, and substantiate their protein expression as potential therapeutic targets. PATIENTS AND
methodsThe mRNA expression of 160 genes identified from microarray was analyzed in qRT-PCR assays of independent 337 snap-frozen NSCLC tumors to develop a predictive signature. A clinical trial JBR.10 was included in the validation. Hazard ratio was used to select genes, and decision-trees were used to construct the predictive model. Protein expression was quantified with AQUA in 500 FFPE NSCLC samples.
resultsA 7-gene signature was identified from training cohort (n = 83) with accurate patient stratification (P = 0.0043) and was validated in independent patient cohorts (n = 248, P < 0.0001) in Kaplan-Meier analyses. In the predicted benefit group, there was a significantly better disease-specific survival in patients receiving adjuvant chemotherapy in both training (P = 0.035) and validation (P = 0.0049) sets. In the predicted non-benefit group, there was no survival benefit in patients receiving chemotherapy in either set. The protein expression of ZNF71 quantified with AQUA scores produced robust patient stratification in separate training (P = 0.021) and validation (P = 0.047) NSCLC cohorts. The protein expression of CD27 quantified with ELISA had a strong correlation with its mRNA expression in NSCLC tumors (Spearman coefficient = 0.494, P < 0.0088). Multiple signature genes had concordant DNA copy number variation, mRNA and protein expression in NSCLC progression.
conclusionsThis study presents a predictive multi-gene assay and prognostic protein biomarkers clinically applicable for improving NSCLC treatment, with important implications in lung cancer chemotherapy and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.